Iron Supplement Therapy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for iron supplement therapy. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
4
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Iron Supplement Therapy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Rockwell Medical Inc 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating iron supplement therapy. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
27
3
29

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Triferic
FERRIC PYROPHOSPHATE CITRATE
 Rockwell Medical Inc 4 75 — 2027-09-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7857977 Triferic method of use 75 2027-09-08
7816404 Triferic method of use 75 2029-04-17
7816404 Triferic method of use 75 2029-04-17
7816404 Triferic method of use 75 2029-04-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7816404 Triferic method of use 75 2029-04-17
7816404 Triferic method of use 75 2029-04-17
7816404 Triferic method of use 75 2029-04-17
7857977 Triferic method of use 75 2027-09-08

Related